# Instillation of Gemcitabine in Patients With Superficial Bladder Cancer

> **NCT00191477** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 355 (actual)

## Conditions studied

- Bladder Neoplasms

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00191477
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-01
- **Primary completion:** 2008-03
- **Final completion:** 2008-06
- **Target enrollment:** 355 (ACTUAL)
- **Why stopped:** The study was stopped early for futility reasons.
- **Last updated:** 2009-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191477, "Instillation of Gemcitabine in Patients With Superficial Bladder Cancer". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00191477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*